Latest News and Press Releases

BRIDGEWATER, N.J., June 13, 2022 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (Nasdaq: HILS) (“Hillstream”, the “Company”), a biotechnology company developing novel therapeutic candidates...

Recent milestones include FDA Orphan Drug Designations for HSB-1216 and HSB-888 World-class scientific advisory team and growing and distinguished patent portfolio remain key competitive advantages...

Developed in partnership with J.P. Morgan and Johnson & Johnson Innovation, the Conference will bring together more than 500 life sciences professionals and thought leadersHillstream’s...

CHESTER, N.J., May 19, 2020 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”) today announced that two abstracts highlighting the progress of HSB-1216 (salinomycin QUATRAMER™)...

Positive pre-clinical data with an emerging validated mechanism of action, Ferroptosis HSB-1216 is a novel therapeutic using the QUATRAMER formulation of a potent anti-Ferroptotic compounds,...

CHESTER, N.J., Nov. 19, 2019 (GLOBE NEWSWIRE) -- Hillstream BioPharma Inc. (“Hillstream”) today announced the addition of clinician-scientist Kwok-Kin Wong, MD, PhD to Hillstream’s Scientific...

CHESTER, N.J., Nov. 04, 2019 (GLOBE NEWSWIRE) -- Hillstream BioPharma, Inc. (“Hillstream”) today announced a collaboration with Ardena to secure manufacturing feasibility and capacity for...

CHESTER, N.J., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Hillstream BioPharma Inc. (“Hillstream”) today announced the renewal of a Cooperative Research and Development Agreement (CRADA) with the National...

CHESTER, N.J., June 12, 2017 (GLOBE NEWSWIRE) -- Hillstream BioPharma Inc. (Hillstream), a biopharmaceutical company focused on developing targeted, safer and more effective cancer therapeutics,...